How to Get Rapamycin (Sirolimus) in Maryland

Maryland Prescribing Rules for Rapamycin

Maryland law permits any physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) with an active Maryland license to prescribe sirolimus. NPs in Maryland gained full practice authority in 2015, meaning they can prescribe independently without a collaborative agreement once they complete a supervised transition period. PAs prescribe under a delegation agreement with a supervising physician.

Telehealth prescribing is legal statewide. The Maryland Board of Physicians requires that an initial provider-patient relationship be established through a synchronous visit (video or audio), after which follow-up consultations and prescription renewals can continue remotely [1]. No in-person visit is required for the initial consultation, which removes a barrier for patients in rural counties like Garrett, Allegany, and Somerset where longevity-focused clinicians are scarce.

The state does not restrict off-label prescribing. A prescriber who determines that sirolimus is medically appropriate for a patient's longevity or immune-modulation goals can write the prescription, document clinical reasoning, and order the necessary monitoring labs. The FDA-approved label for Rapamune lists prevention of renal transplant rejection as the sole indication, so any longevity use is off-label by definition [2].

Step-by-Step Process to Obtain Sirolimus in Maryland

Getting a rapamycin prescription follows a predictable sequence. Here is what to expect.

Step 1: Baseline laboratory work. Before any prescriber will write a sirolimus script, you need recent labs. The standard panel includes a complete blood count (CBC), comprehensive metabolic panel (CMP), fasting lipid panel, fasting glucose or HbA1c, and liver function tests. Some clinicians also request a baseline sirolimus trough level if the patient has used the drug previously. Quest Diagnostics and Labcorp both operate draw sites across Maryland, from Bethesda to Ocean City.

Step 2: Clinical consultation. During the visit, the prescriber reviews lab results, medical history, current medications, and contraindications. Sirolimus interacts with strong CYP3A4 inhibitors (ketoconazole, erythromycin, verapamil) and CYP3A4 inducers (rifampin, carbamazepine), so a medication reconciliation is mandatory [2]. The prescriber then discusses dosing strategy. For off-label longevity protocols, the most studied regimen is a pulsed weekly dose of 5 to 6 mg, based on the PEARL trial design [3].

Step 3: Prescription routing. The prescriber sends the Rx electronically to either a retail pharmacy stocking generic sirolimus or a 503A compounding pharmacy. This choice affects cost and turnaround time.

Step 4: Dispensing and shipping. Retail pharmacies typically fill the script within 1 to 3 business days. Compounding pharmacies may take 3 to 7 business days, depending on order volume and custom formulations.

Telehealth Options for Maryland Residents

Telehealth has become the primary access channel for patients seeking rapamycin for off-label longevity use. Most brick-and-mortar primary care physicians are unfamiliar with mTOR inhibitor protocols outside oncology and transplant medicine. Telehealth platforms specializing in longevity medicine fill that gap.

A typical telehealth consultation costs between $150 and $350 for the initial visit, with follow-ups priced at $75 to $150. These fees are usually not covered by insurance because the visit centers on off-label prescribing. Some platforms bundle the consultation fee with lab orders and a 90-day supply of compounded sirolimus, bringing total quarterly costs to approximately $400 to $700.

Maryland's telehealth parity law (Md. Code, Insurance §15-139) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. Since off-label longevity consultations are rarely a covered service, this parity law has limited practical impact here. It does apply, however, if sirolimus is being prescribed for an FDA-approved or insurer-recognized indication.

Patients should confirm that their telehealth provider holds an active Maryland medical license. The Maryland Board of Physicians maintains a public license verification tool for checking credentials before scheduling.

503A Compounding Pharmacies in Maryland

Maryland licenses 503A compounding pharmacies through the Board of Pharmacy. These pharmacies prepare patient-specific prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act. They can compound sirolimus into custom dosage forms (capsules at specific milligram strengths, flavored suspensions) that commercial manufacturers do not offer.

A 503A pharmacy differs from a 503B outsourcing facility. The 503A model requires a patient-specific prescription before compounding begins, while 503B facilities can produce batches without individual prescriptions. Both types can ship within Maryland, but the patient's prescriber must send the Rx to the specific pharmacy. The distinction matters because pricing and turnaround vary.

Generic sirolimus tablets (1 mg) at a retail pharmacy typically cost $30 to $90 for a 30-day supply using a GoodRx-type discount card. Compounded sirolimus from a 503A pharmacy ranges from $60 to $180 for a comparable supply, depending on the dosage form and compounding complexity. Brand-name Rapamune is substantially more expensive, often exceeding $800 per month without insurance.

Maryland patients can also receive compounded sirolimus shipped from out-of-state 503A pharmacies, provided those pharmacies hold a non-resident pharmacy license issued by the Maryland Board of Pharmacy. This expands access beyond local compounders.

Labs and Monitoring While on Sirolimus

Sirolimus has a narrow therapeutic index for transplant dosing, but off-label longevity protocols use lower and less frequent doses that reduce (without eliminating) the need for monitoring. The PEARL trial (N=150), published in Aging Cell in 2024, used weekly 5 mg dosing and found the regimen was well tolerated over 48 weeks, with no serious adverse events attributable to the drug [3].

Standard monitoring includes:

• CBC every 3 months for the first year. Sirolimus can cause dose-dependent thrombocytopenia and leukopenia. In the PEARL trial, mean platelet counts remained within normal range across the treatment group [3].
• Fasting lipids every 3 to 6 months. Hyperlipidemia is the most common metabolic side effect. A 2020 meta-analysis of mTOR inhibitor trials (N=5,207) reported a 30% incidence of hypercholesterolemia across all doses and indications [4].
• Fasting glucose or HbA1c every 6 months. mTOR inhibition can transiently impair insulin signaling, though weekly pulsed dosing appears to minimize this effect compared to daily dosing regimens [5].
• Sirolimus trough level at 4 to 6 weeks after initiation (drawn immediately before the next scheduled dose). Target trough for off-label longevity use is generally kept below 5 ng/mL, well under the 5 to 15 ng/mL transplant target.
• Liver function tests (AST, ALT) every 6 months.

Quest and Labcorp accept most of these lab orders without prior authorization. Sirolimus trough levels require a specialized immunoassay, which both national labs perform. Cost without insurance ranges from $25 to $75 for the trough level alone.

Maryland Medicaid and Insurance Coverage

Maryland Medicaid covers sirolimus for its FDA-approved indication (prevention of organ transplant rejection) with prior authorization. The PA process requires the prescriber to submit documentation confirming the diagnosis, transplant history, and medical necessity.

For off-label longevity use, coverage is unlikely through any payer. Neither Maryland Medicaid nor commercial insurers in the state (CareFirst BlueCross BlueShield, Kaiser Permanente Mid-Atlantic, Aetna, UnitedHealthcare) routinely cover off-label sirolimus for aging or immune modulation. Patients pursuing this indication should expect to pay out of pocket.

The prior authorization process for transplant patients typically requires:

1. A completed PA request form from the prescriber
2. Documentation of the transplant date and type
3. Lab results showing current renal function and immunosuppressant trough levels
4. A letter of medical necessity if the patient is switching from another immunosuppressant

Processing time is 24 to 72 hours for standard requests and 24 hours for urgent requests under Maryland Medicaid rules. Denials can be appealed through the Maryland Department of Health's fair hearing process.

Dr. Matt Kaeberlein, a biogerontologist at the University of Washington who has published extensively on rapamycin and aging, has stated: "The evidence supporting rapamycin's effect on multiple hallmarks of aging is among the strongest of any pharmacological intervention we have" [6]. This scientific consensus has not yet translated into insurance coverage for longevity use in any U.S. state, including Maryland.

Transferring a Sirolimus Prescription to Maryland

Patients relocating to Maryland or traveling within the state can transfer an existing sirolimus prescription. Maryland Board of Pharmacy regulations permit prescription transfers between pharmacies, including across state lines, for non-controlled substances. Sirolimus is not a controlled substance under federal or Maryland law.

The process requires the receiving Maryland pharmacy to contact the originating pharmacy directly. Both pharmacies verify the prescription details, remaining refills, and prescriber information. Electronic transfers via the Surescripts network are common between chain pharmacies (CVS, Walgreens, Rite Aid). Independent and compounding pharmacies may handle transfers by phone or fax.

One limitation: compounded prescriptions cannot always be transferred because the formulation may differ between pharmacies. If your out-of-state pharmacy compounded a custom sirolimus preparation, you may need a new prescription written to the Maryland compounder's specifications.

Dose Protocols Used in Longevity Medicine

The FDA-approved dose for transplant rejection prevention is 2 mg daily (after a 6 mg loading dose), adjusted to maintain trough levels of 5 to 15 ng/mL [2]. Off-label longevity dosing looks very different.

The weekly pulsed protocol has gained traction based on preclinical data and early clinical trials. In the PEARL trial, participants received 5 mg sirolimus once per week for 48 weeks. This intermittent schedule aims to provide enough mTOR complex 1 (mTORC1) inhibition to activate autophagy and reduce senescent cell burden while avoiding sustained mTORC2 disruption that can impair glucose metabolism [3].

Other protocols used by longevity clinicians include:

• 3 mg weekly for patients over age 70 or those weighing under 60 kg
• 5 mg biweekly as a conservative starting regimen
• 6 mg weekly in patients with prior exposure and documented tolerability
• Cycled protocols of 8 weeks on, 4 weeks off, though published data supporting cycling is limited to animal studies

A 2014 study by Mannick et al. (N=218) demonstrated that low-dose mTOR inhibition (0.5 mg daily everolimus, a rapamycin analogue) enhanced immune function in older adults, improving influenza vaccine response by approximately 20% compared to placebo [7]. This trial, published in Science Translational Medicine, remains one of the strongest pieces of evidence for immune benefits of mTOR inhibition in healthy aging populations.

No protocol has been validated in a large, long-duration randomized controlled trial for human longevity endpoints. Prescribers and patients should understand that all longevity dosing is based on extrapolation from shorter-term safety and biomarker data.

Safety Considerations and Contraindications

Sirolimus carries FDA black box warnings for immunosuppression, increased susceptibility to infection, and increased risk of lymphoma and other malignancies in transplant patients receiving full immunosuppressive regimens [2]. Whether these warnings apply at low, intermittent longevity doses is unknown. No cases of lymphoma or opportunistic infection were reported in the PEARL trial at the 5 mg weekly dose over 48 weeks [3].

Common side effects at longevity doses include mouth sores (aphthous ulcers), reported in roughly 15 to 25% of users across trials, and mild GI discomfort. These are usually self-limiting and resolve within the first 4 to 8 weeks.

Absolute contraindications include:

• Known hypersensitivity to sirolimus or any component of the formulation
• Active systemic infection
• Pregnancy or planned pregnancy (Category C; teratogenic in animal studies)
• Concurrent use of strong CYP3A4 inhibitors without dose adjustment

Relative contraindications include poorly controlled diabetes (HbA1c >9%), severe hepatic impairment, and pre-existing significant cytopenias. Patients with a history of non-melanoma skin cancer should use sun protection rigorously, as mTOR inhibitors may increase photosensitivity.

What Maryland Patients Should Know Before Starting

The gap between scientific interest in rapamycin for aging and the clinical evidence base remains wide. The Interventions Testing Program (ITP), funded by the National Institute on Aging, has consistently shown lifespan extension in mice treated with rapamycin, with effects ranging from 9% to 23% depending on dose, sex, and genetic background [8]. Translating these results to humans requires ongoing clinical trials.

Maryland residents considering rapamycin for longevity should select a prescriber experienced with mTOR inhibitor pharmacology, commit to the monitoring schedule, and maintain realistic expectations about what weekly sirolimus can and cannot do based on current data. The first follow-up visit should occur 6 to 8 weeks after starting the drug, with a sirolimus trough level drawn 6 to 7 days after the most recent dose.